| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 6,644.8 | 6,219.3 | 6,059.17 | 5,963.88 | 5,842.85 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 6,644.8 | 6,219.3 | 6,059.17 | 5,963.88 | 5,842.85 |
Other Operating Income | 58.1 | 62.4 | 70.99 | 134.66 | 132.94 |
Other Income | 92.8 | 50.6 | 11.29 | 290.64 | 257.88 |
Total Income | 6,795.7 | 6,332.3 | 6,141.45 | 6,389.18 | 6,233.67 |
Total Expenditure | 5,971 | 5,562.3 | 4,983.81 | 4,723.3 | 4,460.78 |
PBIDT | 824.7 | 770 | 1,157.64 | 1,665.88 | 1,772.89 |
Interest | 272.3 | 188.2 | 145.49 | 184.1 | 199.71 |
PBDT | 552.4 | 581.8 | 1,012.15 | 1,481.78 | 1,573.18 |
Depreciation | 381.9 | 554 | 381.7 | 348.95 | 339.84 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 202.6 | 181.1 | 172.55 | 269.91 | 335.1 |
Deferred Tax | -104.8 | -88.4 | 44.88 | 27.31 | 0 |
Reported Profit After Tax | 72.7 | -64.9 | 413.02 | 835.61 | 898.24 |
Minority Interest After NP | -4.4 | -3.9 | -0.92 | -0.26 | 0 |
Net Profit after Minority Interest | 77.1 | -61 | 413.94 | 835.87 | 898.24 |
Extra-ordinary Items | 31.8 | 124.3 | 0 | -13.99 | -22.04 |
Adjusted Profit After Extra-ordinary item | 45.3 | -185.3 | 413.94 | 849.86 | 920.28 |
EPS (Unit Curr.) | 4.87 | -3.83 | 26 | 52.48 | 56.39 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 500 | 500 | 500 | 500 | 500 |
Equity | 15.8 | 15.9 | 15.92 | 15.92 | 15.93 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 12.41 | 12.38 | 19.1 | 27.93 | 30.34 |
PBDTM(%) | 8.31 | 9.35 | 16.7 | 24.84 | 26.92 |
PATM(%) | 1.09 | -1.04 | 6.81 | 14.01 | 15.37 |
This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.
Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.
Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.
Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
